IRIS
TENTORI, LUCIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 50.191
EU - Europa 5.432
AS - Asia 3.681
SA - Sud America 520
AF - Africa 39
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 4
Totale 59.876
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 50.092
SG - Singapore 1.900
IT - Italia 1.748
CN - Cina 894
UA - Ucraina 736
DE - Germania 734
BR - Brasile 438
FR - Francia 434
IE - Irlanda 425
HK - Hong Kong 358
RU - Federazione Russa 268
SE - Svezia 266
PL - Polonia 239
GB - Regno Unito 212
FI - Finlandia 160
KR - Corea 145
VN - Vietnam 123
NL - Olanda 85
CA - Canada 62
JP - Giappone 51
IN - India 47
CZ - Repubblica Ceca 33
ID - Indonesia 29
MX - Messico 28
AR - Argentina 26
BD - Bangladesh 26
CO - Colombia 19
AT - Austria 18
ES - Italia 18
TR - Turchia 16
BE - Belgio 15
LT - Lituania 11
ZA - Sudafrica 11
IL - Israele 10
IQ - Iraq 10
IR - Iran 9
MA - Marocco 9
VE - Venezuela 9
BG - Bulgaria 8
CL - Cile 8
EU - Europa 8
PH - Filippine 8
UZ - Uzbekistan 8
EC - Ecuador 7
KG - Kirghizistan 7
CH - Svizzera 6
EG - Egitto 6
PK - Pakistan 5
TN - Tunisia 5
TW - Taiwan 5
MK - Macedonia 4
PE - Perù 4
PY - Paraguay 4
UY - Uruguay 4
AE - Emirati Arabi Uniti 3
AU - Australia 3
BH - Bahrain 3
JO - Giordania 3
KE - Kenya 3
KZ - Kazakistan 3
MY - Malesia 3
TT - Trinidad e Tobago 3
AL - Albania 2
DK - Danimarca 2
GE - Georgia 2
HR - Croazia 2
JM - Giamaica 2
MW - Malawi 2
OM - Oman 2
PS - Palestinian Territory 2
PT - Portogallo 2
SY - Repubblica araba siriana 2
BN - Brunei Darussalam 1
BY - Bielorussia 1
CR - Costa Rica 1
CY - Cipro 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GD - Grenada 1
KH - Cambogia 1
LB - Libano 1
MD - Moldavia 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
RO - Romania 1
SA - Arabia Saudita 1
SN - Senegal 1
SR - Suriname 1
TH - Thailandia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 59.876
Salva come PNG Salva come JPEG
Città #
Woodbridge 15.641
Wilmington 12.699
Houston 12.638
Ann Arbor 1.419
Fairfield 1.117
Singapore 880
Ashburn 734
Jacksonville 662
Chandler 621
Seattle 444
Dublin 399
Beijing 390
Cambridge 376
Hong Kong 355
Medford 312
Rome 289
New York 264
Dearborn 228
Kraków 216
Dallas 183
Santa Clara 169
Lawrence 149
Milan 145
Mülheim 113
Los Angeles 111
The Dalles 97
Buffalo 77
Menlo Park 67
Zhengzhou 67
San Diego 59
Council Bluffs 57
Guangzhou 50
Moscow 46
Boardman 45
Mountain View 42
Ho Chi Minh City 37
Redwood City 35
Munich 34
São Paulo 34
Falls Church 33
Civitavecchia 32
Nuremberg 31
Naples 29
Shanghai 29
San Mateo 28
Palo Alto 26
University Park 26
Chicago 25
Nanjing 25
Phoenix 23
Hefei 22
London 22
Turin 22
Columbus 21
Prague 21
Verona 21
Bari 20
Jakarta 20
Hanoi 19
Norwalk 19
Florence 18
Ottawa 18
Palermo 18
San Francisco 18
Rio de Janeiro 17
Toronto 17
Catania 15
Brescia 14
Brussels 14
Kansas City 14
Kunming 14
Montreal 14
Saint Petersburg 14
Tokyo 14
Denver 13
Nanchang 13
Redondo Beach 13
Atlanta 12
Danville 12
Helsinki 12
Napoli 12
Porto Alegre 12
Stockholm 12
Belo Horizonte 11
Brasília 11
Brooklyn 11
Indiana 11
Pisa 11
Pune 11
Torino 11
Bologna 10
Frankfurt am Main 10
Poplar 10
Warsaw 10
Jinan 9
Salt Lake City 9
Seoul 9
Baghdad 8
Brno 8
Johannesburg 8
Totale 52.313
Salva come PNG Salva come JPEG
Nome #
Gli inibitori della poli (ADP-ribosio) polimerasi (PARP) per superare la chemioresistenza a metilanti e inibitori di topoisomerasi I 1.442
L’attività fisica come terapia complementare: l’esempio delle malattie oncologiche 733
Temozolomide: An Update on Pharmacological Strategies to Increase its Antitumour Activity 635
Common fragile sites in colon cancer cell lines: role of mismatch repair, RAD51 and poly(ADP-ribose) polymerase-1 496
Valproic acid increases the stimulatory effect of estrogens on proliferation of human endometrial adenocarcinoma cells 493
Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells 486
Targeted therapy for brain tumours: role of PARP inhibitors 484
Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk? 476
Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G2/M cell accumulation induced by temozolomide in malignant glioma cells 472
Antitumor and antimetastatic effects of dacarbazine combined with cyclophosphamide and interleukin-2 in Lewis lung carcinoma (3LL) 466
Cilengitide down-modulates invasiveness and vasculogenic mimicry of neuropilin-1 expressing melanoma cells through the inhibition of αvβ5 integrin. 466
Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide 463
Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity 460
A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib 459
Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site 452
Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. 451
Ellagic acid inhibits bladder cancer invasiveness and in vivo tumor growth 451
Apoptotic and genotoxic effects of a methyl sulfonate ester that selectively generates N3-methyladenine and poly(ADP-ribose) polymerase inhibitors in normal peripheral blood lymphocytes 450
Challenging resistance mechanisms to therapies for metastatic melanoma 450
Immunopharmacology of antitumor agents. 448
Chemical xenogenization: antigenic changes of cancer cells induced by triazene compounds 446
Rifampin increases cytokine-induced expression of the CD1b molecule in human peripheral blood monocytes 445
Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components 443
The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma 443
Una medicina che cambia: l’approccio all’ipercolesterolemia. 441
Mutation of the mismatch repair gene hMSH2 and hMSH6 in a human T-cell leukemia line tolerant to methylating agents 440
Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds 440
Role of the mismatch repair system and p53 in the clastogenicity and cytotoxicity induced by bleomycin 440
Exploiting Microglial Functions for the Treatment of Glioblastoma 440
Cytokine-induced expression of CD1b molecules by peripheral blood monocytes: influence of 3'-azido-3'-deoxythymidine 438
Influence of low-dose beta-interferon on natural killer cell activity in breast cancer patients subjected to chemotherapy 437
A novel water-soluble nitrobenzoxadiazole is highly effective against vemurafenib-resistant human melanoma cells 436
Cytokine-induced expression of CD1b molecules by peripheral blood monocytes: Influence of 3'-azido-3'-deoxythymidine 432
Oral administration of PARP inhibitor GPI 18180 increases the anti-tumor activity of temozolomide against intracranial melanoma in mice. 431
Pharmacological strategies to increase the antitumor activity of methylating agents 427
New aspects of immune responses against mycobacteria: immunopharmacology studies 427
Thymic selection of the T-cell repertoire 426
Chemotherapy in hairy cell leukemia. Preliminary results of a nonaggressive regimen 424
Novel Glutathione S-Transferase Inhibitor Enhances Temozolomide Efficacy Against Malignant Melanoma 52nd Annual Meeting of the Italian Cancer Society. Lost in translation: bridging the gap between cancer research and effective therapies 423
Effects of diheptyldiselenide (DDS) on human tumor cell lines and on peripheral blood mononuclear cells 423
Comparative studies between in vitro and in vivo effects of human beta-interferon on natural killer activity and its relevance to immunochemotherapy 423
Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines 422
Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors 420
Differentiation of Ia-reactive CD8+ murine T cells does not require Ia engagement. Implications for the role of CD4 and CD8 accessory molecules in T cell differentiation 419
Drug-mediated increase of susceptibility of human lung cancer to NK or LAK effector cells 418
Induction of apoptosis in thymocytes by prostaglandin E2 in vivo 416
Role of PARP, NF-kB and telomerase in necrosis induced by selective methylation of N3-adenine. 415
DNA damaging agents can induce celll cycle arrest in different phases of mitosis 415
Mutations of human DNA topoisomerase I at poly(ADP-ribose) binding sites: modulation of camptothecin activity by ADP-ribose polymers. 415
Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide. 413
Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (ADP-ribose) polymerase inhibitor 412
Inhibition of O-6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic coils to apoptosis induced by temozolomide 412
Role of DNA repair pathways in the control of common fragile sites expression. 411
Modulation of GDF11 expression and synaptic plasticity by age and training 411
IL-2 reverses the inhibition of cytotoxic T-cell responses induced by 5-(3,3' dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) in vitro 410
Poly (ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis 410
Neuropilin-1 expressing melanoma cells as a model to study the aggressiveness of metastatic melanoma 410
The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma 409
Primary cultures of microglial cells for testing toxicity of anticancer drugs. 408
Effect of rifampin on CD1b expression and double-negative T cell responses against mycobacteria-derived glycolipid antigen 407
Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer 407
Monoclonal antibodies to CTLA-4 with focus on ipilimumab 406
Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis 406
Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan. 405
Cytotoxic and clastogenic effects of a DNA minor groove binding methyl sulfonate ester in mismatch repair deficient leukemic cells 404
null 404
Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding 404
Pharmacological inhibition of poly(ADP-ribose) polymerase activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells 403
Activity against melanoma of an anti-vascular endothelial growth factor receptor-1 (VEGFR-1) monoclonal antibody that does not hamper ligand binding 403
Apoptotic and clastogenic effects of methylating agents, alone or combined with poly(ADP-ribose) polymerase inhibitor, in peripheral blood lymphocytes 402
Poly (ADP-ribose) polymerase inhibitor increases apoptosis and reduces necrosis induced by a DNA minor groove binding methyl sulfonate ester 401
PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy 401
Doping and Cancer 400
Acute rejection of interferon-treated leukemia cells injected into lethally irradiated syngeneic mice 400
VEGFR-1 derived peptide specifically inhibits PlGF and VEGF-B-induced migration of endothelial cells and in vivo angiogenesis. 399
Residual telomerase activity: a marker of cell survival after exposure to gamma radiation in vitro 398
Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype. 397
Inhibition of metastasis induced by triazene derivatives in mice bearing Lewis Lung Carcinoma (3LL): role of protein kinase C 395
MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination. 394
Evidence of the crucial role of the linker domain on the catalytic activity of human topoisomerase I by experimental and simulative characterization of the Lys681Ala mutant 393
Inhibition of poly(ADP-ribose) polymerase (PARP) increases the therapeutic efficacy of the G-quadruplex ligand RHPS4/irinotecan combination in colon cancer xenografts 392
Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent. 391
The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells 391
Pharmacological inhibition of poly (ADP-ribose) polymerase (PARP) activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells and increases temozolomide sensitivity of PARP-1 silenced melanoma cells. 390
Influenza di farmaci antivirali o antimicobatterici sulla proliferazione di monociti umani e sulla espressione del CD1b. Secondo Progetto di ricerca Tubercolosi 390
Acquired hemoglobin H disease in a case of refractory anemia with excess of blasts (RAEB) evolving into acute nonlymphoid leukemia 389
Oral administration of the PARP-1 inhibitor GPI 15427 increases the anti-tumor activity of irinotecan against colon carcinomas 388
Proliferation and production of IL-2 and B cell stimulatory factor 1/IL-4 in early fetal thymocytes by activation through Thy-1 and CD3 388
Systemic administration of the PARP inhibitor GPI 15427 increases the anti-tumor activity of temozolomide in melanoma, glioma and lymphoma preclinical models in vivo 386
Oral administration of the PARP-1 inhibitor GPI 15427 increases the anti-tumor activity of irinotecan and temozolomide combination against colon carcinoma 385
In vitro antitumor activity of 3'-desamino-3'(2-methoxy-4-morpholinyl) doxorubicin on human melanoma cells sensitive or resistant to triazene compounds 385
Influenza di farmaci antivirali o antimicobatterici sulla proliferazione di monociti umani e sulla espressione del CD1b 385
Mutation of the mismatch repair gene hMSH2 and hMSH6 in a human T-cell leukemia line tolerant to methylating agents 384
Chemopotentiation by PARP inhibitors in cancer therapy 383
In vivo anti-angiogenic potential of a peptide that inhibits VEGFR-1 homodimerization and PlGF-induced migration of endothelial cells. 383
Generation of an immortalized human endothelial cell line as a model of neovascular proliferating endothelial cells to assess chemosensitivity to anticancer drugs. 383
PARP-1 inhibitor: a novel approach to enhance efficacy of chemotherapy. 382
Platelet-derived growth factor C and calpain-3 are modulators of human melanoma cell invasiveness. 382
Targeting angiogenesis with poly(ADP-ribose) polymerase inhibitors 377
PARP inhibitors for cancer treatment: an update on current clinical trials. 377
Totale 43.444
Salva come PNG Salva come JPEG
Categoria #
all - tutte 116.544
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 116.544
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.554 0 0 0 0 0 961 966 793 209 170 345 110
2021/20221.494 64 214 110 66 32 110 95 68 106 107 76 446
2022/20231.923 202 107 61 268 115 430 163 97 180 41 176 83
2023/20241.176 100 36 81 65 109 342 86 60 47 47 65 138
2024/20253.572 139 858 398 208 136 312 150 192 350 181 323 325
2025/20262.320 407 252 776 334 490 61 0 0 0 0 0 0
Totale 60.107